Article ; Online: Roles of HIF-1α signaling in Mycobacterium tuberculosis infection: New targets for anti-TB therapeutics?
Biochemical and biophysical research communications
2024 Volume 711, Page(s) 149920
Abstract: Tuberculosis (TB), a deadly infectious disease induced by Mycobacterium tuberculosis (Mtb), continues to be a global public health issue that kill millions of patents every year. Despite significant efforts have been paid to identify effective TB ... ...
Abstract | Tuberculosis (TB), a deadly infectious disease induced by Mycobacterium tuberculosis (Mtb), continues to be a global public health issue that kill millions of patents every year. Despite significant efforts have been paid to identify effective TB treatments, the emergence of drug-resistant strains of the disease and the presence of comorbidities in TB patients urges us to explore the detailed mechanisms involved in TB immunity and develop more effective innovative anti-TB strategies. HIF-1α, a protein involved in regulating cellular immune responses during TB infection, has been highlighted as a promising target for the development of novel strategies for TB treatment due to its critical roles in anti-TB host immunity. This review provides a summary of current research progress on the roles of HIF-1α in TB infection, highlighting its importance in regulating the host immune response upon Mtb infection and summarizing the influences and mechanisms of HIF-1α on anti-TB immunological responses of host cells. This review also discusses the various challenges associated with developing HIF-1α as a target for anti-TB therapies, including ensuring specificity and avoiding off-target effects on normal cell function, determining the regulation and expression of HIF-1α in TB patients, and developing drugs that can inhibit HIF-1α. More deep understanding of the molecular mechanisms involved in HIF-1α signaling, its impact on TB host status, and systematic animal testing and clinical trials may benefit the optimization of HIF-1α as a novel therapeutic target for TB. |
---|---|
MeSH term(s) | Humans ; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Mycobacterium tuberculosis/drug effects ; Mycobacterium tuberculosis/metabolism ; Mycobacterium tuberculosis/immunology ; Signal Transduction/drug effects ; Tuberculosis/drug therapy ; Tuberculosis/immunology ; Tuberculosis/metabolism ; Tuberculosis/microbiology ; Animals ; Antitubercular Agents/therapeutic use ; Antitubercular Agents/pharmacology ; Molecular Targeted Therapy/methods |
Chemical Substances | Hypoxia-Inducible Factor 1, alpha Subunit ; Antitubercular Agents ; HIF1A protein, human |
Language | English |
Publishing date | 2024-04-09 |
Publishing country | United States |
Document type | Journal Article ; Review ; Research Support, Non-U.S. Gov't |
ZDB-ID | 205723-2 |
ISSN | 1090-2104 ; 0006-291X ; 0006-291X |
ISSN (online) | 1090-2104 ; 0006-291X |
ISSN | 0006-291X |
DOI | 10.1016/j.bbrc.2024.149920 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 116: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.